Clinical trial · no report yet · Phase 3
BRUIN-CLL-313
A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
- NCT05023980 ↗
- Active not recruiting
- Loxo Oncology, Inc.
- 78 commentary sources found
- Deep
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| YouTube | 36 | |
| Podcasts | 21 | |
| X threads | 20 | |
| X videos | 1 |
The trial
ClinicalTrials.gov- Official title
- A Phase 3 Open-Label, Randomized Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab in Untreated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Phase
- Phase 3
- Status
- Active not recruiting
- Conditions
- Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma
- Interventions
- Pirtobrutinib; Bendamustine; Rituximab
- Arms
- Arm A - Pirtobrutinib · Experimental
- Arm B - Bendamustine Plus Rituximab · Active comparator
- Enrollment
- 282
- Primary outcomes
- Arm A Compared to Arm B: Progression-free Survival (PFS), Assessed by Independent Review Committee (IRC)
- Sponsor
- Loxo Oncology, Inc. with Eli Lilly and Company
- Start
- Sep 23, 2021
- Primary completion
- Jul 11, 2025
- Results posted
- Yes
- Registry record
- NCT05023980 · updated Sep 25, 2026
Publications
linked from the registry- Eyre TA, Hess LM, Masoudi E, Jen MH, Abhyankar S, Graham-Clarke PL, Bhandari NR, Maguire P, Winfree KB, Tracey M, Taipale KL, Davids MS. Efficacy of Pirtobrutinib Monotherapy in Treatment-Naive Chronic Lymphocytic Leukemia: A Bayesian Network Meta-Analysis of Randomized Controlled Trials. Cancers (Basel). 2026 Feb 18;18(4):660. doi: 10.3390/cancers18040660. PubMed 41749915
- Jurczak W, Kwiatek M, Czyz J, Roberto de Mattos E, Eom KS, Egle A, Panovska A, Popova ZG, Shih HJ, Casado Montero LF, Sportoletti P, Hua VM, D'Olimpio JT, Iida S, Ito R, Bao K, Fink A, Su W, Ruppert AS, Levy A, Wrobel T. BRUIN CLL-313: Randomized Phase III Trial of Pirtobrutinib Versus Bendamustine Plus Rituximab in Untreated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. J Clin Oncol. 2026 Feb 20;44(6):466-475. doi: 10.1200/JCO-25-02380. Epub 2025 Dec 9. PubMed 41363773